365betapp苹果版下载【首頁】

0431-81311122

行业动态

梯瓦$8.25亿收购Labrys公司获偏头痛药物LBR-101

2015-04-01

来源:生物谷 2014-06-04

2014年6月4日讯 /生物谷BIOON/ --以色列仿制药巨头梯瓦(Teva)6月3日宣布,已与美国生物技术公司Labrys Biologicals签署了一项最终收购协议。根据协议,梯瓦将支付2亿美元的前期付款,以及高达6.25亿美元的里程碑或然付款。此次收购,梯瓦将获得一种慢性发作性偏头痛药物LBR-101,该药目前正处于IIb期临床,预计销售峰值将达到20-30亿美元。

梯瓦的目标是,到2020年成为疼痛领域的全球领导者。收购Labrys,将为梯瓦增加一个重要的偏头痛预防维度,目前该公司已拥有广泛的疼痛(偏头痛、癌性疼痛和慢性疼痛)护理特许专营权,包括一系列实验性药物、已获批药物和已上市药物。

今年1月,梯瓦耗资1.44亿美元收购NuPhthe获得了Zecuity,该药是一种偏头痛贴片,是FDA批准用于成人急性偏头痛的唯一一款偏头痛贴剂处方药,可以透过皮肤主动输送舒马曲坦(Sumatriptan)。此外,梯瓦也正在开发一种预防潜在滥用和缓释版的疼痛药物氢可酮。

LBR-101是一种全人源化单克隆抗体,能够结合降钙素基因相关肽(CGRP),目前处于IIb期临床,用于慢性和发作性偏头痛的预防。LBR-101最初由Rinat神经科学公司(于2006年被辉瑞收购)开发。目前,LBR-101已成功完成5个I期临床试验。


英文原文:Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growing Pain Care Franchise

Adds LBR-101, Labrys’ Phase IIb anti-CGRP monoclonal antibody for the prevention of chronic and high frequency episodic migraine. Peak sales potential of $2-3 billion.
Teva ideally positioned in the transformational pain market with a wide range of new chemical and biologic entities and NTEs to treat a broad spectrum of pain disorders
JERUSALEM & SAN MATEO, Calif.--(BUSINESS WIRE)--Jun. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities.
Teva will acquire Labrys for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch milestones. Potential peak sales for LBR-101 are estimated to reach $2 to $3 billion.
With the goal of becoming a global leader in pain by 2020, the Labrys acquisition adds a significant migraine prophylaxis dimension to Teva’s extensive pain care franchise, which includes a range of investigational, approved and marketed treatments for migraine, cancer pain and chronic pain.
Labrys is developing LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) currently in Phase IIb clinical trials for prevention of chronic and episodic migraine. Teva’s acquisition of the LBR-101 program targeting high frequency episodic and chronic migraine clearly complements the recent addition of Zecuity, an innovative therapy for the acute treatment of migraine, obtained through the acquisition of NuPathe. This ability to treat both acute and chronic migraine builds on Teva’s broader pain portfolio, which was recently further strengthened by positive pivotal Phase III results achieved by Teva’s potential abuse-deterrent extended release hydrocodone. The results gave a clear indication, in a clinical setting, of the promise of Teva’s proprietary technology with potential abuse-deterrent properties in a range of opioid medications.
“More than 8.5 million people in the US, EU and Japan (G7) suffer from episodic or chronic migraine requiring preventative treatment, a condition that can destroy their quality of life,” said Michael Hayden, Teva’s President of Global R&D and Chief Scientific Officer. “CGRP is a well-validated target in migraine, and Labrys has progressed the development of LBR-101 with scientific rigor and excellence. With its long half-life, target specificity and favorable pharmacokinetic profile allowing for infrequent, and convenient, subcutaneous administration, LBR-101 represents a very exciting biologic product candidate, and much needed option, for the management of this truly debilitating condition.”
“Teva is the ideal company to continue Labrys’ efforts to rapidly advance the LBR-101 program and bring a much needed product to market,” said Steven P. James, Labrys’ President and Chief Executive Officer. “Since closing a Series A investment round in 2013, Labrys has made remarkable strides advancing LBR-101 in a robust Phase 2 development program and attracting a high caliber company in Teva to complete clinical development.”
The closing of this transaction is subject to antitrust clearance and satisfaction of other conditions.
About LBR-101
LBR-101 (formerly RN-307) is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a well-validated target in migraine. It is currently in Phase IIb clinical trials for prevention of episodic and chronic migraine. LBR-101, originally discovered by Rinat Neuroscience (bought by Pfizer in 2006), was acquired by Labrys from Pfizer in 2012. LBR-101 has successfully completed five Phase I trials with 94 healthy volunteers dosed with active drug. Results were published in Cephalalgia, the official journal of the International Headache Society, in December 2013, and presented at the 2014 annual meeting of the American Academy of Neurology. A sixth Phase 1 study (bridging study) tested IV and subcutaneous doses (24 participants received active medication). Both intravenous and subcutaneous administrations were well tolerated. LBR-101 exhibited a long terminal half-life which supports once-monthly subcutaneous dosing. Most treatment-related adverse events were mild, transient and resolved spontaneously. The maximum tolerated dose has not been identified. LBR-101 was not associated with any clinically relevant patterns of change in vital signs, ECG parameters, or laboratory findings.
Proof of efficacy has been observed for several small-molecule CGRP antagonists in the symptomatic (acute) relief of migraine. However, liver toxicity or formulation difficulties have limited their use in migraine prophylaxis. Chronic migraine is characterized by headaches on at least 15 days per month and high frequency episodic migraine shares many similarities with chronic migraine. Patients with this condition are at a high risk of transformation to chronic migraine, and have similar unmet needs due to a paucity of currently approved preventive medications. These preventive medications require daily use, are not effective in a large percentage of patients, and are commonly associated with adverse events. Consequently, prophylactic treatment of episodic and chronic migraine continues to present considerable challenges, and there remains a significant medical need for new, safe and effective migraine prophylactic treatment options.
About Labrys Biologics
Labrys Biologics is a private, venture-financed development stage biotechnology company focused on the preventive treatment of migraine. Labrys' lead candidate, LBR-101 (formerly RN-307), is an anti-CGRP monoclonal antibody for the prevention of chronic and high frequency migraine currently in Phase 2b clinical development. In December 2012, Labrys raised a Series A of $31 million backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.


地址:吉林省长春市高新技术产业开发区锦湖大路1357(E)宝孚大厦4006室 电话:0431-81311122
版权所有:长春力太生物科技有限公司 吉ICP备14006071号-1

建站技术支持长春庞智科技